Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin

Inclusion Criteria: * Histologically proven germ cell cancer: gonadal (including ovarian) or extragonadal, seminomatous or non seminomatous, or clinical presentation of a GCT with elevated AFP level and/or hCG level (\> or =to 100 x ULN) when a biopsy was not available * Metastatic GCT patients: * Progression disease defined as \> 10% increase in hCG and/or AFP markers (and/or documented progressive disease \[PD\]) during a platinum-based chemotherapy or less than 6 months after the last cycle (in the case of growing non seminomatous tumor, without increased markers, a histological documentation of malignant tumor was required, to exclude growing mature teratoma) * At least 1 prior line of chemotherapy containing CDDP + etoposide; (prior regimen with high dose chemotherapy and hematopoietic stem cell support was permitted) * Eastern Cooperative Oncology Group PS (ECOG PS) grade \< or =to 2 * At least 1 bidimensionally measurable lesion by imaging (CT scan) of \> or =to 20 mm outside an irradiated area OR significantly increased tumor markers \> 2 x ULN (on \> or =to 2 consecutive tests, even in the absence of measurable lesions) * Age \> or =to 18 * Adequate bone marrow reserve * Neutrophil count \> or =to 1500/mm3 * Platelets \> or =to 100,000/mm3 * Renal function:Creatinine \< 3 x ULN * Liver function:Transaminases \< or =to 2.5 x ULN, total bilirubin \< 1.5 x ULN (if liver metastases, transaminases \< or =to 5 x ULN) * Laboratory values obtained in the week preceding study entry * Neurosensory \< or =to grade 1 NCI CTC * Signed informed consent obtained prior to all study procedures Exclusion Criteria: * Concomitant high-dose steroids (except for antiemetic prophylaxis) * Pregnancy, breast-feeding or absence of contraception in sexually active patients * Prior treatment with oxaliplatin or taxanes * History of second malignancy, except for cured non melanoma skin cancer or excised in situ cervical carcinoma * Symptomatic cerebral and/or leptomeningeal metastasis (irradiated brain metastases not requiring corticosteroid treatment were allowed) * Treatment with another experimental drug or anticancer agent or participation in another clinical study within 30 days prior to study * Other serious illness or uncontrolled infection * Psychological, social or geographical situation preventing regular follow-up * Primary tumor in brain/central nervous system